{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:21:52Z","timestamp":1788351712048,"version":"build-2803163510"},"reference-count":53,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the patient characteristics and treatment patterns, effectiveness, safety and patient-reported outcomes (PROs) of sarilumab in routine clinical practice, used as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective Sarilumab (Prefilled Syringe\/Pen) Observational Study\u2013Japan (PROFILE-J) was a 52-week, prospective, non-interventional, observational study conducted across Japan. Adult patients with RA initiating sarilumab were enrolled. Effectiveness endpoints included Clinical Disease Activity Index (CDAI) scores, disease activity and PROs. Safety endpoints included treatment-emergent adverse events (TEAEs) and other clinically relevant safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1998 patients (monotherapy, n=567; combination, n=1431), the mean age was 66.6 years, with 63.2% aged \u226565 years and 67.9% na\u00efve to biologic DMARDs. Sarilumab retention at week 52 was 67.5%. Effectiveness analysis population included 1715 patients (monotherapy, n=461; combination, n=1254). Baseline mean CDAI scores (21.2) decreased to low disease activity range (9.7) at week 12; mean changes from baseline were \u221213.6 and \u221213.1 at week 24 and \u201314.2 and \u221214.9 at week 52 for monotherapy and combination therapy respectively. Other measures, including PROs, showed similar improvements in both groups. In the safety population, TEAEs occurred in 44.6% of patients, with a slightly lower rate observed in monotherapy (40.2%) than in combination therapy (46.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study described real-world treatment patterns of sarilumab, highlighting frequent initiation in biologic DMARD-na\u00efve patients, particularly among older adults. Sarilumab demonstrated sustained effectiveness and a consistent safety profile with no new safety signals, supporting its use as monotherapy or combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCT1071190016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006446","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:50:54Z","timestamp":1778601054000},"page":"e006446","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J)"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Hanami","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-3881","authenticated-orcid":false,"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Yokohama Rheumatology Clinic, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-3518","authenticated-orcid":false,"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyasu","family":"Ushio","sequence":"additional","affiliation":[{"name":"Rheumatology, Ushio Clinic, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Okano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, National Hospital Organisation Tokyo Medical Center, Meguro, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onobori","sequence":"additional","affiliation":[{"name":"Rheumatology, Onobori Clinic, Tsukuba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery, Showa Inan General Hospital, Komagane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Center, Mabi Memorial Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-1519","authenticated-orcid":false,"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Faculty of Medicine Graduate School of Medical Sciences, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamanishi","sequence":"additional","affiliation":[{"name":"Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Aichi Developmental Disability Center, Kasugai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Saitama Medical University, Iruma, Japan"},{"name":"Keio University School of Medicine, Shinjuku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[{"name":"National Hospital Organisation Tokyo National Hospital, Kiyose, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Environmental Epidemiology, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Faculty of Medicine, Toho University, Meguro, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026090205003863000_12.2.e006446.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2026090205003863000_12.2.e006446.2","first-page":"S295","article-title":"Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis","volume":"18","author":"Gibofsky","year":"2012","journal-title":"Am J Manag Care"},{"key":"2026090205003863000_12.2.e006446.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005383","article-title":"Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021","volume":"11","author":"Tang","year":"2025","journal-title":"RMD Open"},{"key":"2026090205003863000_12.2.e006446.4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"The Lancet"},{"key":"2026090205003863000_12.2.e006446.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.05.001"},{"key":"2026090205003863000_12.2.e006446.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026090205003863000_12.2.e006446.7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026090205003863000_12.2.e006446.8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203485"},{"key":"2026090205003863000_12.2.e006446.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"2026090205003863000_12.2.e006446.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2026090205003863000_12.2.e006446.13","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338"},{"key":"2026090205003863000_12.2.e006446.14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2026090205003863000_12.2.e006446.15","first-page":"929","article-title":"Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026090205003863000_12.2.e006446.16","unstructured":"Regeneron . Kevzara (sarilumab) approved by FDA for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA). Available: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/kevzarar-sarilumab-approved-fda-treatment-active-polyarticular\/ [Accessed Jul 2025]."},{"key":"2026090205003863000_12.2.e006446.17","unstructured":"US Food and Drug Administration . KEVZARA (sarilumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf [Accessed 24 Jun 2025]."},{"key":"2026090205003863000_12.2.e006446.18","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/rheumatology\/kead062","article-title":"Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis","volume":"62","author":"Burmester","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026090205003863000_12.2.e006446.19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026090205003863000_12.2.e006446.20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-019-1856-4","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan","volume":"21","author":"Tanaka","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026090205003863000_12.2.e006446.21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026090205003863000_12.2.e006446.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"2026090205003863000_12.2.e006446.23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026090205003863000_12.2.e006446.24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"2026090205003863000_12.2.e006446.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"2026090205003863000_12.2.e006446.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2026090205003863000_12.2.e006446.27","unstructured":"Japan Pharmaceuticals and Medical Device Agency (PMDA) . KEVZARA\u00ae s.c. injection - precribing information. 2023. Available: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_3999444G1022_1_08 [Accessed 25 Jun 2025]."},{"key":"2026090205003863000_12.2.e006446.28","first-page":"167","article-title":"The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"J Rheumatol"},{"key":"2026090205003863000_12.2.e006446.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.11465"},{"key":"2026090205003863000_12.2.e006446.30","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1151-6"},{"key":"2026090205003863000_12.2.e006446.31","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"2026090205003863000_12.2.e006446.32","doi-asserted-by":"crossref","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire\u2014general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2026090205003863000_12.2.e006446.33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/mr\/roae057","article-title":"Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and \u226565\u2009years): A post hoc analysis of Japanese Phase 3 clinical trials","volume":"35","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s40744-024-00715-9","article-title":"Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study","volume":"11","author":"Kivitz","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026090205003863000_12.2.e006446.35","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkac002","article-title":"Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany","volume":"6","author":"Tony","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2026090205003863000_12.2.e006446.36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2026090205003863000_12.2.e006446.37","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/rheumatology\/kead539","article-title":"Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study","volume":"63","author":"Yamada","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026090205003863000_12.2.e006446.38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/mr\/roae006","article-title":"Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study","volume":"34","author":"Matsui","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"2021","journal-title":"Eur Geriatr Med"},{"key":"2026090205003863000_12.2.e006446.40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/mr\/roab066","article-title":"Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.41","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026090205003863000_12.2.e006446.42","first-page":"SP338","article-title":"Cost of biologic treatment persistence or switching in rheumatoid arthritis","volume":"24","author":"Gu","year":"2018","journal-title":"Am J Manag Care"},{"key":"2026090205003863000_12.2.e006446.43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEOR.S108730","article-title":"Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy","volume":"9","author":"Degli Esposti","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026090205003863000_12.2.e006446.44","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/rheumatology\/keab676","article-title":"Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis","volume":"61","author":"Burmester","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026090205003863000_12.2.e006446.45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","article-title":"Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)","volume":"30","author":"Kameda","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/mr\/roae051","article-title":"Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study","volume":"35","author":"Kameda","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026090205003863000_12.2.e006446.47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jinf.2023.02.014","article-title":"Rising incidence of Pneumocystis pneumonia: A population-level descriptive ecological study in England","volume":"86","author":"Pates","year":"2023","journal-title":"J Infect"},{"key":"2026090205003863000_12.2.e006446.48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-020-02194-z","article-title":"Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026090205003863000_12.2.e006446.49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood.V73.1.108.108","article-title":"In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs","volume":"73","author":"Ulich","year":"1989","journal-title":"Blood"},{"key":"2026090205003863000_12.2.e006446.50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu035"},{"key":"2026090205003863000_12.2.e006446.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026090205003863000_12.2.e006446.52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026090205003863000_12.2.e006446.53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:01:00Z","timestamp":1788350460000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006446"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006446","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}